| Ytd | -42.16% | |
| 1y | -34.49% |
| Open | 11.79 | Prev Close | 11.96 | Low | 11.55 | High | 11.90 | Mkt Cap | 683.75M |
| Vol | 25.58K | Avg Vol | 718.20K | EPS | -2.13 | P/E | -5.62 | Forward P/E | -6.94 |
| Beta | 0.44 | Short Ratio | 1.06 | Inst. Own | 37.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 17.53 | 200-d Avg | 22.34 | 1yr Est | 51.82 |
OCS News
British outsourcer Mitie has agreed to be acquired by rival OCS Group International for a total v
U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potent
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers
Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the
Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pri
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to
Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the p
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pr
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowe
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52
Guggenheim analyst Yatin Suneja initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rati
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and raises
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the pr
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and rais
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.63) per share which missed the analyst
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and mai
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with
PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring th
